A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC)(DeLLphi-309)
Clinical Trial Grant
Awarded By
Amgen, Inc.
Start Date
May 14, 2025
End Date
May 13, 2030
Awarded By
Amgen, Inc.
Start Date
May 14, 2025
End Date
May 13, 2030